A similar decrease in adenoma count and COX-2 expression was reported when trametinib, a small-molecule mitogen-activated protein kinase kinase (MEK) inhibitor, was administered to APC mutant mice [51], suggesting that the COX-2 expressing subset could also be maintained by MEK signaling. This evidence concerns the gene MAP2K7 and adenoma.